Mississippi State University

Scholars Junction
Theses and Dissertations

Theses and Dissertations

8-17-2013

Assessment of Canine Immunity using Computational and Flow
Cytometric Approaches
Kriston Weaver

Follow this and additional works at: https://scholarsjunction.msstate.edu/td

Recommended Citation
Weaver, Kriston, "Assessment of Canine Immunity using Computational and Flow Cytometric Approaches"
(2013). Theses and Dissertations. 769.
https://scholarsjunction.msstate.edu/td/769

This Graduate Thesis - Open Access is brought to you for free and open access by the Theses and Dissertations at
Scholars Junction. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of
Scholars Junction. For more information, please contact scholcomm@msstate.libanswers.com.

Automated Template B: Created by James Nail 2011V2.01

Assessment of canine immunity using computational and flow cytometric approaches

By
Kriston Weaver

A Thesis
Submitted to the Faculty of
Mississippi State University
in Partial Fulfillment of the Requirements
for the Degree of Master of Science
in Veterinary Medical Science
in the College of Veterinary Medicine
Mississippi State, Mississippi
August 2013

Assessment of canine immunity using computational and flow cytometric approaches
By
Kriston Weaver
Approved:

_________________________________
Lesya M. Pinchuk
Associate Professor
Basic Sciences
Co-Major Professor

_________________________________
Andrew J. Mackin
Professor and Graduate Coordinator
Clinical Sciences
Co-Major Professor

_________________________________
Andrea S. Varela-Stokes
Assistant Professor
Basic Sciences
Committee Member

_________________________________
Bindu Nanduri
Assistant Professor
Basic Sciences
Committee Member

_________________________________
Kent Hoblet
Dean
College of Veterinary Medicine

Name: Kriston Weaver
Date of Degree: August 17, 2013
Institution: Mississippi State University
Major Field: Veterinary Medical Science
Co-Major Professors: Dr. Lesya M. Pinchuk and Dr. Andrew J. Mackin
Title of Study:

Assessment of canine immunity using computational and flow
cytometric approaches

Pages in Study: 59
Candidate for Degree of Master of Science
The Affymetrix GeneChip® Canine Genome 2.0 microarray is re-annotated using
AgBase tools, up-to-date ID mapping and GO annotations associated with publicly
available gene products updated on this array. This re-annotation makes the array more
useful for researchers using the canine microarray for biological discovery. We use flow
cytometry to determine if liposomal clodronate (LC) is an acceptable alternative to
surgical splenectomy to facilitate detection of subclinical infection with Babesia canis in
potential blood donor greyhounds. Our study shows that LC is not a reliable means of
exposing babesiosis in greyhounds with a recent history of infection. We evaluate the
effect of depletion of antigen presenting cells on regulatory T cells (Tregs) in dogs treated
with LC by multi-color flow cytometry. We demonstrate that LC promotes increases in
the CD4+CD25+FOXP3+ Tregs affecting mostly the CD4+CD25lowFOXP3+ Tregs subset
suggesting a role of monocytes in naïve T cell priming and differentiation into Tregs.
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CHAPTER I
INTRODUCTION

There is an ongoing movement to utilize high-throughput functional genomics
platforms to derive biologically significant information from lists of numerous identifiers
and accessions. In addition, there is a need for up-to-date accessions to facilitate data
availability and ease of use for various fields of research. The canine model, which is
used in several areas of medical research, has the potential to provide translational
information to promote medical research if data are readily available.
Babesia is an intracellular protozoan parasite that exploits red blood cells (RBCs).
It is the causative agent of babesiosis, which is not only considered an emerging disease
in the U.S., but is also a major concern in veterinary practice. Disease caused by Babesia
canis is commonly subclinical in greyhounds, which, in turn, become chronic carriers. As
the most common blood donors used in veterinary medicine, greyhounds must be
screened for Babesia to prevent a parasite transmission from blood donors to recipients
that could develop potentially fatal babesiosis. In the past, screening of potential blood
donors was performed using a surgical splenectomy to reveal circulating protozoa. As the
spleen is responsible for removing infected RBCs, absence of the spleen will lead to
observable parasitemia indicating that the animal is unfit to join the blood donor pool.
However, this invasive practice has dropped out of favor, because it leaves the animal
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permanently immune-suppressed. Here, we explore the possibility of a medical
splenectomy utilizing liposome encapsulated clodronate.
Liposomal clodronate (LC) is used to cause transient immune suppression in both
research and clinical settings by depleting monocytes, macrophages and immature
dendritic cells (DCs) via apoptosis. Here, greyhounds exposed to Babesia were treated
with differing levels of LC and Babesia infected RBC numbers were evaluated via flow
cytometric analysis over the course of treatment. We propose that LC treatment could be
an alternative to surgical splenectomy for potential blood donors.
Also, for the first time, regulatory T cell (Tregs) numbers were evaluated in the
absence of professional antigen presenting cells (APCs), monocytes, macrophages and
immature DCs. Tregs are a subset of T cells defined as CD4+CD25+FOXP3+, and that are
critical for suppression and regulation of normal canine immune responses. Canine Tregs
are poorly understood, but new staining techniques provide a key to unearthing much
needed information on this critical cell type.
Three specific aims accomplished in this thesis research are as follows:
Functional Annotation of the Affymetrix GeneChip® Canine Genome 2.0
Microarray
Hypothesis: By re-annotating the Affymetrix Canine Genome 2.0 microarray, we
will increase the number of annotations provided for the microarray as a
whole and the quality of annotations provided for the array.
Objective: To improve the existing functional annotation of the Affymetrix
Canine Genome 2.0 microarray.
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To achieve this objective: A digital file including all Affymetrix probeset
identifiers on the microarray was re-annotated and updated using AgBase
tools. This updated information was made publicly available in a userfriendly format at the Mississippi State University Agbase website.
Use of liposomal clodronate (LC) to facilitate detection of subclinical Babesia canis
infection in potential blood donor greyhounds
Hypothesis: Transient immune suppression by liposomal clodronate (LC) will
facilitate detection of subclinical Babesia canis infection in potential
canine blood donors.
Objective: Evaluate the role of liposomal clodronate in the development of
parasite infection in erythrocytes of greyhounds with known exposure to
Babesia canis (PCR and anti-Babesia antibody positive) but without
evidence of productive Babesia infection in their red blood cells (flow
cytometry and blood smear negative).
To achieve this objective: Four greyhounds with a history of varying levels of
positivity for exposure/confirmed presence of Babesia were given a low,
medium, and high dose of liposomal clodronate. To evaluate the effect of
the drug, the levels of parasite-infected red blood cells in peripheral blood
was measured using specific single color flow cytometric analysis and
results analyzed by one-way ANOVA statistics.
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The effects of selective LC-dependent removal of professional antigen presenting
cells (APCs), monocytes, macrophages and immature dendritic cells (DCs) on
the numbers and phenotypes of CD4+CD25+FOXP3+ regulatory T cells
Hypothesis: Monocytes/macrophages and immature DCs are the major APC
populations shaping protective adaptive immune responses in dogs, as has
been demonstrated in humans and mice, and their impaired function leads
to immune suppression through a conversion of naïve T cells into
suppressive FOXP3-expressing Tregs.
Objective: Evaluate the role of professional APCs (monocytes/macrophages/DCs)
in the generation of FOXP3-expressing regulatory T cells in normal dogs
and dogs exposed to Babesia canis.
To achieve this objective: The numbers of Tregs in four greyhounds previously
exposed to Babesia canis were assessed following the administration of
low, medium, and high doses of liposomal clodronate. The numbers and
phenotypes of Tregs and the levels of CD14+ monocytes of four normal
Walker hounds treated with the medium dose of LC, and Tregs were
observed. For both studies, multiple color flow cytometric analysis was
performed and the results were analyzed with one way ANOVA statistics.
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CHAPTER II
REVIEW OF PERTINENT LITERATURE

Microarray and Gene Ontology
The use of microarrays in research generates a large amount of data that must be
translated into biologically relevant information. In order to accomplish this, researchers
use annotation, the practice of attaching biological information to sequences. This
information can then be interpreted by researchers themselves or entered into modeling
tools such as pathway analysis and Gene Ontology(GO) enrichment tools [1]. There are
two components of annotation: structural annotation and functional annotation. Structural
annotation is the identification of demarcation of the genomic boundaries of individual
functional elements within the genome sequence and includes providing accessions and
identifiers for commonly used public databases. This tends to occur as the genome
sequence is assembled and continues as new information is acquired. Functional
annotation associates a gene product’s functional information with the gene product itself
and is not commonly done during genome sequencing [1, 2]. GO has become the
standard for functional annotation. It is a structured network consisting of defined terms
and relationships between them that describe three attributes of gene products: molecular
function, biological process, and cellular component [3]. These three independent
ontologies are dynamic and while having a common language, they exist in a network
that changes constantly as more information is acquired [4]. Using GO annotation,
5

researchers can take large amounts of data generated from microarrays and assign
biological significance to their results based on the function, process, or component they
are associated with. Researchers spend large amounts of time and money to annotate their
singular dataset. In this project, we sought to re-annotate the Affymetrix Canine Gene
Chip 2.0 microarray that was annotated in 2006. As information content of databases
such as GO keeps changing, there is a need for re-annotation of microarrays and
dissemination of this updated information to the public. The end result is improved ability
to perform analysis of canine samples.
Liposomal Clodronate
Clodronate or dichloromethylene-bisphosphonate is being used in various types of
treatments and experiments in many different fields of the scientific and medical
communities [5]. When taken into professional phagocytes, including both DCs and
monocytes/macrophages, clodronate is metabolized to adenosine 5’ triphosphate with the
end result being the lysis of the mitochondrial membrane within the host
monocytes/macrophage, which leads to the induction of apoptosis [6, 43], therefore
depleting the number of viable monocytes/macrophages and DCs that are available for
immune response. A recent study, however, has argued that clodronate causes cell death
via necrosis rather than apoptosis as previously reported [7]. If that is the case, the
cytotoxicity of clodronate could very well cause adverse effects in local tissues when
released at cell lysis.
When administered as a free pharmaceutical, bisphosphonates such as clodronate
are considered to be “bone-seeking molecules” [7], and only very small amounts of the
drug are taken up via phagocytosis. Thus, the resulting intracellular concentrations are
6

too small to induce the most often desired apoptosis [5]. In order to circumvent this,
clodronate is often administered in the liposome encapsulated formation. This prolongs
the amount of time the molecule spends in circulation and increases the chance of
phagocytosis by professional phagocytes [7]. In instances when the immune response
may be detrimental to the overall health of the patient, clodronate is one way that we may
suppress both the innate and adaptive responses.
Liposomes are tiny vesicles composed of one or more concentric phospholipid
bilayers, and they have been found to be efficient methods of delivering water soluble
drugs to phagocytes [5]. Size and charge of the liposome are important characteristics to
take into consideration when developing treatments or experiments. It has been found
that the optimal liposome is negatively charged and has a size of 85±20nm. If too large,
the particle runs the risk of inducing the production of pro-inflammatory cytokines such
as IL-6, TGF-α, and IL-1β that can cause further damage when treating conditions such
as autoimmune diseases. If too small, they can have no effect at all [7].
Liposomes are known to enhance phagocytosis in monocytes/macrophages, but
there are at least two conditions that must be met in order for the encased clodronate to
induce apoptosis in these cells. First, the phagocytosis of a liposome-encased clodronate
is not enough to ensure apoptosis. There are many cell types that will take in this
molecule, but the cells must also have the mechanisms required to lyse the liposomal
membrane to release the clodronate contents. Second, the intracellular concentration of
clodronate must reach a threshold. If the concentration is too low, apoptosis may not
occur. In one study, activated monocytes were observed to have higher levels of
phagocytosis and therefore had higher levels of associated apoptosis when compared to
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resting or non-activated monocytes. Overall, the intracellular concentration of clodronate
regulates the cytotoxic effects or degree of cell death achieved by a single dose of
liposome-encased clodronate [5].
Many scientists are using liposome-encased clodronate to deplete the numbers of
monocytes/ macrophages and DCs in the course of an immune response for many
different types of experimental studies. LC has been used to provide controls for
experiments evaluating the role of monocytes and macrophages in muscle injury [8] and
even in diseases such as acute gout [9]. LC is being used to treat various autoimmune
diseases due to its selective targeting of disease-related monocytes and macrophages [5],
and it has been used in the study of dengue fever to prove that monocytes and
macrophages are critical elements in controlling the virus [10]. In 2004, a study showed
that by depleting monocytes and macrophages by administration of liposome-encased
clodronate, hyperalgesia was decreased in part due to the decrease in pro-inflammatory
mediators produced by those cell types [6]. However, when administering liposomal
clodronate systemically, there is not a significant amount of monocytes/macrophage
depletion in specific sites. In these cases where a specific tissue is being evaluated, direct
local injections are effective in lowering monocyte/ macrophage numbers for several
days. Depletion percentages for circulating monocytes/macrophages have been reported
as high as 70%, and for certain populations of monocyte-derived tissue macrophages has
been anywhere from 15-60% [6].
In 2005, a method utilizing LC’s macrophage depletion characteristics was
developed that allowed for the acceleration of alveolar macrophage reconstitution [11].
Also, LC has been used to decrease the instance of dissemination and brain invasion by
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Cryptococcus neoformans. The causative agent of cryptococcosis, Cryptococcus
neoformans is thought to use monocytes as a type of “Trojan horse” that can carry it to
various organs including the spleen and lungs and even across the blood brain barrier
[12]. Another study describes how the act of depleting macrophages can generally be
both good and bad. It exacerbates early aortic lesions allowing for increase in collagen
content which can cause a widening or growth to be observed. On the other hand, the
depletion of macrophages does decrease the production of pro-inflammatory cytokines as
previously stated [13].
All in all, encapsulation inside liposomes enhances the effectiveness of clodronate
as an immune response inhibitor. Liposome-encased clodronate has widespread uses in
both research and treatment, but should be selected for use on a case-by-case basis. It has
both beneficial effects as well as adverse effects, and those must be weighed carefully.
Babesia
Babesia canis is an intracellular protozoan parasite carried by ticks, in particular
Rhipicephalus sanguineus ( the brown dog tick), which invades canine red blood cells
(RBCs). Transmission from tick to canine host is complete after a 2-3 day feeding
attachment by the tick [14, 15]. Once in the canine host circulatory system, the organism
attaches to RBCs and is internalized via endocytosis [16]. Once in the cytoplasm of the
host’s RBCs, then the organism is free to reproduce via binary fission resulting in rupture
of current RBC and infection of local RBCs [14].
It is known that Rhipicephalus sanguineus transmits the causative agent of canine
babesiosis in greyhounds in the United States. Babesia canis subspecies vogeli, and
disease caused by this protozoan has been recognized in greyhound kennels [14].
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Greyhounds are the most commonly used blood donors in veterinary medicine, because a
high percentage of the breed are universal blood donors, have high hematocrits, gentle
dispositions, and easy to access jugular veins [17]. Greyhounds and their propensity for
babesiosis causes concern in blood transfusion recipients, because a transfusion with
Babesia-infected blood commonly leads to potentially devastating babesiosis. In donor
recipients of Babesia-infected blood, severe babesiosis can lead to multiple organ
dysfunction syndromes, septic shock, or even death [14, 18]. In puppies or adult dogs,
babesiosis can often develop alongside a secondary disease. These cases are often
characterized by fever, lethargy, anorexia and jaundice. Clinically, evidence may indicate
hemolytic regenerative immune-mediated anemia, leukocytosis, and thrombocytopenia
[19, 20, 14]. In greyhounds, it is often hard to diagnose babesiosis since it is most
commonly a mild infection with non-specific clinical signs, and affected dogs can
become chronic sub-clinical carriers [18].
Accepted methods for detection of babesiosis include microscopic identification
of the organism on fresh blood smears, serologic testing using an IFA (indirect
fluorescent antibody test), PCR (polymerase chain reaction) assay targeting the Babesia
spp. small subunit ribosomal RNA (ribonucleic acid) gene in the blood, and flow
cytometric evaluation of RBCs [14].There are limitations to some of these tests. Blood
smears utilizing Giemsa stains are not sensitive tests for detecting Babesia, because it is
hard to visualize the organism unless a moderate to high parasitemia is present [14, 21].
When running antibody tests such as IFA, it can be hard to distinguish active infection
from one that has already cleared due to the persistence of antibodies within the host’s
immune system [18, 22]. Flow cytometry also relies on a detectable parasitemia. In
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instances where tests are positive, donors must be rejected to prevent possible
repercussions due to transfusions with infected blood. Although PCR is a definitive test
for Babesia canis, this is not a technique most clinics have quick and easy access to, and
PCR positivity alone does not permit quantitation of the number of infected RBCs. For
this thesis research, the focus turned to flow cytometric analysis. Several methods for
quantifying red blood cells infected with Babesia via flow cytometry have been
successful: the use of HE (hydroethidine) in DMSO (dimethyl sulfoxide) for staining was
utilized here [22, 23].
Regulatory T cells
Although they are well documented in human and murine research, little is known
about the functional significance of regulatory T cells (Tregs) in the canine. However, it
is apparent that Tregs are an important constituent of healthy function of the host immune
system. Tregs may be either thymus-derived naturally occurring Tregs or Tregs that are
induced in the periphery from conventional peripheral CD4+ T cells [24, 25]. Regulatory
T cells are responsible for maintaining tolerance and preventing autoimmunity by
retaining the ability to suppress the activation and function of effector T cells and antigen
presenting cells (APCs) via their suppressive actions, which include both direct and
indirect suppression. Direct suppression used against effector T cells can be considered
an activation-dependent process, but requires cell-cell interactions in order actively
suppress effector T cells [26]. On the other hand, indirect suppression, in evidence versus
APCs, includes induction of the enzyme IDO (indoleamine 2,3-dioxygenase) which
causes the development of a strong immunosuppressive agent and induces more Tregs
[30].
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In normal systems, when activated or increased in numbers to a suitable
concentration, Tregs can help to prevent autoimmune dysfunction of the host system [31,
33], or they may exacerbate any ongoing pathology [32, 34, 35, 36, 37, 38, 39]. Although
more research is needed, studies have shown that a nuclear transcription factor FOXP3
(forkhead box P3 transcription factor) is necessary for the natural generation of naïve T
cells into regulatory T cells with suppressive functions. Without FOXP3, the
recognizable immunosuppressive function can be lost [27, 28, 29]. Currently, it has been
shown that conventional T cells stimulated via antigen in the presence of essentials such
as TGF-β, IL-10, and retinoic acid will be induced to Tregs [40, 41, 42].
There is still much research to be performed in order to comprehensively detail
the function of Tregs and their role in the canine immune response, but studies are
beginning to show that functions of Tregs in canines are similar to known functions
described in human and murine models.
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CHAPTER III
FUNCTIONAL ANNOTATION OF THE AFFYMETRIX CANINE 2.0
MICROARRAY

Abstract
Researchers using high-throughput functional genomics platforms such as
microarrays must be able to derive biologically relevant insights from the results, which
are returned as lists of numerous identifiers and accessions. This is a problem due to the
amount of time and resources needed to turn those accessions into applicable data. The
lack of functional annotation associated with arrays is also a challenge for modeling array
data. Despite an increase in the amount of canine genomics research, the annotation files
provided for the Affymetrix GeneChip® Canine Genome 2.0 microarray contain
functional annotations for only 14.5% of transcripts represented on this array. We reannotated the Affymetrix canine array, providing updated database identifiers and new
functional annotations. Here we linked the Affy probe IDs to identifiers from commonly
used databases to create an ID mapping file which can be used to facilitate data sharing
between differing databases. In addition, we linked these same gene products to existing
functional annotation using the Gene Ontology (GO), and provided new GO annotation
where none existed. After remapping, we identified 10,737 existing GO annotations for
5,127 of the newly mapped gene products represented on the array. In addition, we added
70,148 annotations for 16,966 gene products. Thus, we have provided annotations for
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94% of this array, which represents a seven-fold increase in the number of gene products
than were originally annotated. The resultant data is publicly available at the AgBase
website (http://agbase.msstate.edu) and will be periodically updated during standard
database updating procedures. The new data provided enables canine researchers to more
efficiently functionally model their Affymetrix array datasets and translate array data into
additional knowledge.
Background
The canine genome was initially released in July 2004 by the BROAD Institute’s
Dog Genome Project, and then a new version was released in May 2005 [4, 5]. A
commonly used canine microarray, the Affymetrix GeneChip® Canine Genome 2.0
(GPL: 3738), with probes for over 18,000 canine mRNA/EST transcripts and over 20,000
non-redundant predicted genes, was designed to help obtain biologically relevant
information from this genome (6). The identifier mappings and GO annotations
associated with this array were last updated in 2006 [7].
The outdated or lack of functional annotations associated with microarrays
hinders researchers who wish to model their array data results to obtain biologically
relevant information. Thus, despite the importance of canine array research, only 5% of
available datasets generated using this array have been published, while only 4% of
available datasets have been published for all canine array platforms (based on Gene
Expression Omnibus database, 2/2013), Figure 3.1. This represents thousands of dollars
of research that has not yet been translated to biological relevance for biomedical and
veterinary research. Moreover, these figures are likely to under-represent the magnitude
of the problem, because not all datasets from canine array research will have been
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submitted as researchers try to obtain annotations. However, re-annotation of arrays with
the most up-to-date functional annotations can lead to significant changes in the
interpretation of array datasets [8].

Figure 3.1

Estimation of data generated using canine assays.

Representative of canine datasets in GEO as of 2/2013.
Annotation is the practice of attaching biological information to sequences, and it
is this information that is used not only by researchers but also by functional modeling
tools such as pathways analysis and Gene Ontology (GO) enrichment analysis tools.
There are two components of annotation: structural annotation and functional annotation.
Structural annotation is the identification of individual functional elements within the
genome sequence and includes providing accessions and identifiers for commonly used
public databases. This is generally initiated as the genome sequence is assembled and
continues on-going as new information is acquired. Functional information, alternatively,
associates a gene product’s functional information with the gene product itself and is not
commonly performed during genome sequencing [1].
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GO has become the standard for functional annotation, and is a structured
network consisting of defined terms and relationships between them that describe three
attributes of gene products: Molecular Function, Biological Process, and Cellular
Component [2]. These three independent ontologies are dynamic and while having a
common language, they exist in a network that changes constantly as more information is
acquired [3].
To make functional modeling in canine research more accessible for researchers,
we re-annotated the largest and most frequently used microarray, the GeneChip® Canine
Genome 2.0 Array from Affymetrix. This updated array annotation will be made publicly
available at AgBase at http://www.agbase.msstate.edu.
Methods
Affymetrix Array Files and Array Statistics
The Affymetrix GeneChip® Canine Genome 2.0 (GEO platform accession GPL:
3738) has probes that represent 18,000 canine mRNA/EST transcripts and over 20,000
non-redundant predicted genes. We obtained canine array dataset numbers from the Gene
Expression Omnibus (GEO) database (http://www.ncbi.nih.gov/geo) using specific
searches (Figure 3.1). The number of canine datasets submitted was obtained using the
search criteria: dog[organism]. The number of those datasets that were linked to
publications was obtained using the refined search criteria: dog[organism] AND “gds
pubmed”[filter]. The number of datasets submitted from only the Affymetrix GeneChip®
Canine Genome 2.0 array, was obtained using search criteria: GPL3738. The number of
those datasets that were linked to publications was obtained by the refined search criteria:
GPL3738 AND “gds pubmed”[filter].
20

Accession Mapping
Since different functional modeling tools often require different public database
accessions or identifiers, accession mapping of Affy probe IDs to multiple public
databases was done to provide an up-to-date, comprehensive cross-mapping file to
support functional modeling. The ArrayIDer tool is available for public use and can be
accessed via the AgBase website. This tool accepts numerous ID types, including
Affymetrix probeset identifiers which result from the use of Affymetrix microarrays. A
document is then generated by the tool which matches these probeset identifiers to a list
of equivalent identifiers used by other publically available databases such as UniProtKB,
Ensembl, RefSeq, and Entrez Gene. ID types preferred were UniProtKB (Universal
Protein Knowledgebase) and RefSeq, with UniProtKB identifiers desired due to their
high-quality manual annotations. Ensembl, RefSeq, and Entrez identifiers were mapped
back to any corresponding UniProtKB and RefSeq protein identifiers using the publically
available BioMart application provided by the Ensembl website [7]. All RefSeq protein
identifiers were then checked against the National Center for Biotechnology Information
(NCBI) database to update this list of identifiers with any revisions or deletions. Updated
RefSeq protein identfiers were then mapped to UniProt identifiers using the publically
available ID Mapping application [8]. These updated identifiers were compiled into a
single ID Mapping file that is available online at the AgBase Array Annotation section.
Figure 3.2 outlines the workflow of re-mapping and re-annotating the GeneChip® Canine
Genome 2.0 microarray.
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Figure 3.2

Workflow schematic showing the process of ID mapping and linking GO
annotation.

Functional annotation begins by accession mapping through ArrayIDer which divides the
input file into broad categories: ESTs, BROAD, Entrez, Ensembl, UniProKB, Genbank
RefSeq. UniProtKB and Genbank RefSeq are sent through GORetriever which pulls
existing GO annotations while the rest undergo manual biocuration. ESTs, BROAD, and
Entrez accessions go through sequence analysis of functional motifs and domains.
GO Annotation
Since a key step in functional modeling is GO enrichment analysis, canine gene
products from the ID Mapping file were linked to GO annotations. Currently, there is no
dedicated GO annotation for dog gene products and the main source of existing GO
annotation are the UniProtKB annotations provided by the EBI GOA Project [1]. We
used the ID mapping file to identify any array probes that had a mapping to UniProtKB
and used GORetriever [2] to get these annotations. Next we provided GO annotations for
the remaining gene products represented on the array based on their type of database
accession (which indicates the type of data available for the corresponding gene product).
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Expressed Sequence Tags (ESTs): Since there is no experimental functional data
available for ESTs, these sequences can only be GO annotated based upon sequence
analysis of functional motifs and domains [9]. EST sequences identified form the canine
microarray were downloaded from the dbEST, prepared as FASTA files and this data was
submitted to the InterProScan program [3]. The resulting InterPro identifiers were
mapped to GO using the InterPro2GO mapping file [4]. These annotations are given the
GO evidence code “Inferred from Electronic Annoation” (IEA) and provide broad
functional information that can be used to predict function and support hypothesis testing.
BROAD: These identifiers are associated with the BROAD Institute of MIT and
Harvard and the canine genome project. Retrieving annotations for this subset of
identifiers is still currently ongoing. Updated annotations will be added to the publically
available files as they are retrieved.
UniProtKB and RefSeq Identifiers: Using the GORetriever tool that is provided to
the public by AgBase [2], all existing GO annotation for probes on the microarray
associated with UniProtKB and RefSeq identifiers were separately annotated through
critical analysis of experimental data of published literature using Gene Ontology
Consortium (GOC) guidelines. The resulting compilation of updated GO annotations for
all gene products associated with the Affymetrix GeneChip® Canine 2.0 microarray were
compiled into a single file and will be made publicly available at the AgBase website in
the Array Annotations section after quality check is done using GOC guidelines [6].
GAQ Score
The GO Annotation Quality (GAQ) Score [5] measures the breadth of GO
annotation, the level of detail of the annotation, and the type of evidence used to make the
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annotation to provide a quantitative measure of the overall quality of the GO annotations.
All updated anntoations retrieved were combined into a single file that was arranged into
the gene associated file format 2.0, and then uploaded into the AgBase tool in a delimited
form. Output form this tool provides a summary containing the total GAQ score, the
number of non-redundant gene products, and the mean GAQ.
Results and Discussion
Since functional annotation is continually changing as more data is added, to
derive biologically relevant functional information from arrays, scientists need ready
access to the most up-to-date annotation. Although microarrays are used to study canine
systems, only a small fraction of the data is published [Figure 3.1]; this lack of functional
annotation is hindering biological modeling of this data. For example, the Affymetrix
canine microarray was last annotated in May 2006, although it represents 36% of datasets
submitted in GEO. Our re-annotation provides increased amounts of functional
information and shows that the overall quality of this annotation has also increased.
Moreover, we provide annotated data in a format that will facilitate functional analysis
and make it publicly available for GO enrichment analysis tools.
The Affymetrix GeneChip® Canine Genome 2.0 microarray (GPL:3738) contains
over 18,000 probesets which represent over 20,000 gene products [10,11]. Prior to
remapping, the original 18,342 unique probeset identifiers from the array were mapped to
a total of 26,818 unique identifiers and accessions from UniProtKB, RefSeq, and
Ensembl which are commonly used public databases. Since each probeset is mapped to
its equivalent accession in each database, this ID mapping file creates a useful look up
table used to retrieve data from each of these databases. The identifiers represented on
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this array were as follows: 6% UniProtKB, 55% RefSeq, 10% Ensembl, 1% Entrez Gene,
1% BROAD, and 27% ESTs [Figure 3.3]. From the small percentage of UniProtKB in
comparison to the larger percentage of the RefSeq and ESTs, we can see that high-quality
information linked to this array is limited. With the highest quality annotations being
UniProtKB, this initial mapping indicates a need for re-mapping and re-annotation with
the purpose of increasing the percentage of UniProtKB accessions. For example, the
majority of mapping is to RefSeq accessions. Of those 15,024 accessions, less than 1% of
the identifiers mapped to known proteins, designated NP. The remaining accessions were
mapped to predicted proteins, designated XP. Thus, less than 1% of those RefSeq
accessions have undergone manual biocuration to confirm or deny their predicted
function.

Figure 3.3

Breakdown of identifier types before and after re-mapping.

The increase in the number of UniProtKB indicates that the quality of the annotations
retrieved for the new ID mapping file will also increase.
After re-mapping, the probeset identifiers from the array were linked to a total of
29,909 unique identifiers and accessions. This increase in the number of identifiers
associated with this array is due to probeset identifiers mapping to more than one
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identifier. The new breakdown of identifier types represented is as follows: 22%
UniProtKB, 50% RefSeq, less than 3% Ensembl, 1% BROAD, and 24% ESTs [Figure
3.3]. As indicated previously, the higher the number of UniProtKB accessions, the higher
the quality of total annotations associated with the array. UniProtKB accessions are the
highest quality identifiers because of the biocuration the identifiers must undergo and the
comprehensive nature of information linked to the identifiers. Although the majority of
identifiers once again mapped to RefSeq accessions, as a result of the re-mapping, there
was a marked improvement in the quality of annotations to be retrieved based on the
increase in the percentage of UniProtKB identifiers. The complete results can be found at
the AgBase website.
In the original annotation file (released in 2006), the Affymetrix annotation file
provided with the canine array linked the probesets with 15,822 GO annotations for 2,608
gene products represented on the array. After re-mapping these identifiers, we linked the
updated probeset with 10,737 GO annotations representing 5,127 gene products. This
decrease in the amount of GO annotations is partly due to the new set of gene products
associated with the array and partly because of revisions to the GO annotations (as
functional annotations are improved, some previous annotation may be deleted or
revised). Since our remapping of the array probesets decreased the initial functional
annotation associated with these gene products, we next provided additional GO
annotation for these gene products.
Since the EBI GOA Project provides GO annotations for UniprotKB proteins and
AgBase biocurators provide GO annotation for Genbank(RefSeq) proteins with no
equivalent UniProtKB entry, we found that there were already 41,155 existing GO
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annotations for UniProtKB accessions and 69,821 existing GO annotations for
Genbank(RefSeq) proteins. Moreover, AgBase biocurators manually added detailed,
experimental base GO annotations from published papers, providing another 321 GO
annotations for 44 gene products (this work is ongoing). Since 98% of the
Genbank(RefSeq) proteins are designated as “XP” or “unknown proteins” (that is, there
is no direct evidence that these proteins are translated, but rather they are predicted based
on EST and homology to other known mammalian proteins), it is unlikely that these
proteins will have any direct experimental evidence as to their function. Thus, we focus
our manual biocuration on the 1053 UniProtKB proteins that currently have no GO and
the 97 “known” Genbank(RefSeq) proteins (designated with “NP” prefix).
Likewise, EST sequences also have no functional literature. However, because
ESTs are typically short sequences, they cannot be reliably linked to orthologous genes in
other species. Providing a first pass functional annotation for these sequences requires an
analysis of functional motifs and domains to identify sequences with conserved function
[9]. Using this approach, we provided 22,006 annotations for 7,291 ESTs on the array
that had no equivalent mRNA or proteins sequence. However, 99.2% of the gene
products were annotated as ND or “no data”. While this may be considered as a “null”
result, it does alert researchers to the fact that there is currently no functional data
available for these transcripts; further functional classification must await improved
sequence annotation. However, these initial GO annotations can be added to the AgBase
database in order to perform periodical updates to add more functional information as it
becomes available.
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Overall, we added 70,148 GO annotations for 16,966 gene products. This
represents an increase from an initial 14% of the gene products represented on the array
associated with functional annotation to 94% of the gene products represented on this
array having some GO annotations. This represents almost a seven-fold increase in the
number of gene products than were initially annotated [Figure 3.4]. Moreover, analysis of
the GO quality (using the AgBase GAQ Score tool) mirrors this data in indicating an
increase in quality of mean GAQ score from the initial 87.4% to 90.4%.

Figure 3.4

Gene products represented on the array that are linked to GO annotation.

Of the 18,000 gene products represented, the original annotation file available with the
Affymetrix GeneChip® Canine Genome 2.0 microarray only provided GO annotations
for 14% of the entire array. After re-mapping and re-annotation, we have provided GO
annotations for 94% of all gene products represented on this array.
Conclusion
By re-analyzing and updating the annotation data associated with the Affy canine
array we were able to provide a comprehensive list of public database accessions that the
probes represent and to associate these gene products with GO annotation to facilitate
functional modeling. In doing so, we have not only updated the canine gene products
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represented on the array to reflect the newest genome release, but we have also improved
the functional annotation linked with these products by almost seven-fold. Since 95% of
the canine datasets produced from this array (and submitted to GEO as of 2/2013) remain
unpublished, our goal is to facilitate functional modeling of data produced by this and
other canine arrays. By making this data publicly available we expect to facilitate the use
of canine functional genomic data to provide insights into canine biology, rather than to
generate long lists of transcripts. With the advent of new sequencing technologies that are
producing even larger and more complex transcriptome data sets, it is becoming
increasingly important that functional annotation is provided for those gene products
which have functional data available.
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CHAPTER IV
USE OF LIPOSOMAL CLODRONATE (LC) TO FACILITATE DETECTION OF
SUBCLINICAL INFECTION WITH BABESIA CANIS IN POTENTIAL
BLOOD DONOR GREYHOUNDS

Background
An emerging disease in the U.S., babesiosis has become a particular problem in
greyhound kennels. As greyhounds, often retired from the racetrack, are the most
common breed to be used as blood donors, babesiosis has a critical impact on the use of
blood donors in veterinary medicine [3]. In greyhounds, babesiosis is most commonly
associated with Babesia canis vogeli, a protozoan parasite of red blood cells (RBCs) that
is carried by the brown dog tick, Rhipicephalus sanguineus [1]. It is thought to take 2-3
days of attachment by the tick for transmission of the sporozoite stages of the organism to
occur [4].
Although babesiosis is usually subclinical in greyhounds, it can cause serious
illness, even fatalities, in dogs inadvertently transfused with infected blood [5, 6].
Identification of donors with occult Babesia infection is therefore essential for
transfusion safety. Techniques utilized to detect the presence of Babesia include direct
microscopic observance of blood smears, IFA (indirect fluorescent antibody) serology,
PCR (polymerase chain reaction) [2, 6], and counting infected cells using a laser-based
cell counter such as flow cytometry [7, 8]. Each method has its own draw backs. For
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example, the blood smear depends on active parasitemia, but in greyhounds the infection
is commonly subclinical with animals being chronic carriers [6]. The organism therefore
might not show up when using only direct microscopy. This is also a draw back with
detection via flow cytometry. When running antibody tests, it is hard to prove whether a
positive test is the result of a current infection or an infection already cleared by the
host’s immune system. PCR, on the other hand, is a definitive test for Babesia infection,
but it is not a technique that most clinics have readily available. It does not allow for
quantitation of the number of infected RBCs.
In the past, deciding whether or not an animal could become a blood donor was as
easy as surgically removing the spleen. Since the spleen is required to help fight infection
with blood-borne pathogens, splenectomy would allow for a flare-up of any blood borne
parasite. This highly invasive procedure is no longer recommended, and an alternative is
needed. In this study, we sought to evaluate the use of liposomal clodronate (LC) to
facilitate the detection of subclinical infection with Babesia canis in potential blood
donor greyhounds.
Liposomal clodronate has been shown to deplete macrophages and monocytes by
induction of apoptosis via lysis of the mitochondrial membrane [9,10]. This results in an
overall transient immune suppression that loses effect when the drug is no longer present
in therapeutic levels. Since macrophages are needed to recognize and remove Babesiainfected RBCs from circulation, it has been proposed that LC may ‘unveil’ hidden
babesiosis in infected greyhounds. The main objective of this study was to determine if
LC would reveal any sequestered organisms in dogs with a history of exposure to
Babesia canis
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Methods
Dogs
Four healthy Babesia canis-exposed adult greyhounds and one Walker hound
(used as a non-treated control) was used for this study. Health was confirmed based on
physical examination, blood smear, complete blood count (CBC), serum biochemistry,
and urinalysis. The greyhounds had a history of being variably positive for Babesia canis
infection: one was IFA negative/PCR low positive, another was IFA and PCR negative
but came from the same source as the other affected dogs and was housed and transported
with them, another was IFA positive/ PCR high positive, and a final dog was IFA
negative/ PCR positive. Greyhound results also varied between IFA/PCR testing dates.
At the time of administration of LC, all dogs had become negative on every test for
Babesia canis for at least three months. All animals were cared for according to
guidelines approved by the Mississippi State University Institutional Animal Care and
Use Committee (IACUC), and were housed in a university setting under standard
conditions. The Mississippi State University animal facilities and program are accredited
by the American Association for Accreditation of Laboratory Animal Care.
Treatment
Liposome clodronate (LC) (dichloromethylenedisphosphonic acid disodium salt,
SIGMA, encapsulated into liposomes at Colorado State University) was administered to
four greyhounds at low (0.5 ml/kg), medium (1 ml/kg), and high (2 ml/kg) doses via slow
intravenous infusion at a constant rate into an indwelling peripheral venous catheter over
a 90-minute period, using an infusion pump.
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Study Design
A schematic of the study design is shown in Figure 4.1. Briefly, the study began
with baseline monitoring for levels of infected RBCs in greyhounds prior to treatment
with LC and subsequent assessment of levels of infected RBCs in LC-treated dogs
(Figure 4.1).

Figure 4.1

LC treatment timeline.

Arrows L (yellow), M (blue), H (red) indicate the low, medium, and high dose
treatments. Each dash indicates a RBC assessment time point (three times a week).
(D) represents the number of RBC assessment time points in the study.
Reagents
BD Pharm Lyse™ (10X) lysing solution (BD Biosciences) was used to remove
red blood cells from the white blood samples collected in EDTA tubes. Hydroethidine
(HE) or dihydroethidium (Invitrogen D1168) in DMSO (Sigma D2650) at 1:2000 was
used to stain any nuclear components within RBCs for analysis by flow cytometry.
Cell Preparation
White Blood Cells (as positive controls)
To remove red blood cells (RBCs), whole blood samples collected in EDTA were
incubated with BD Pharm Lyse ™ lysing buffer for 15 minutes in the dark at room
temperature, gently vortexing every 5 minutes. The remaining cell populations were
washed, incubated with a 1:2000 hydroethidine solution for 30 minutes at 37°C, then
were washed and analyzed by flow cytometry.
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Red Blood Cells
Whole blood samples collected in EDTA were washed and buffy coats were
discarded. RBCs were incubated with a 1:2000 hydroethidine solution for 30 minutes at
37° C, then were washed and the level of HE inclusion was analyzed by flow cytometry.
Flow Cytometry
Canine RBCs were gated based on their relative size and granularity using
forward and side scatters (FSC and SSC, respectively) with FACSCalibur Flow
Cytometer (Becton Dickinson). Data were analyzed using FlowJo 7.6.4 Software (Tree
Star, Inc.). The staining resulting from inclusion of HE into the RBC was analyzed by
using single histogram statistics (Figure 4.2).
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Figure 4.2

Assessment of RBCs exhibiting HE inclusion by flow cytometry.

Canine red blood cells were gated using forward and side scatters (A). RBCs stained by
inclusion of HE into the nuclei were analyzed by using single color histogram statistics
(B-negative control; C-experimental sample).
Statistical Analysis
RBCs exhibiting inclusion of HE as a specific population was expressed as a
percentage of the total RBC numbers. Then, data was subjected to a one-way analysis of
variance (ANOVA) followed by Fisher’s LSD multiple comparison post hoc test and are
presented as means + SD. The level of significance for all tests of effects was set at
P<0.05.
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Results and Discussion
Many canine vector-borne diseases can cause serious, even life-threatening
clinical conditions in dogs, with a number also having significant zoonotic potential and
affecting human populations [1, 11]. Since greyhounds are one of the most common
breeds utilized as blood donors in veterinary medicine, accurate and efficient detection of
canine vector borne diseases such as babesiosis is essential for preventing potentially
devastating transfusions of infected blood. Here we used flow cytometry to determine the
level of Babesia canis infection in greyhounds treated with LC.
Consistent baseline negative status on assays for Babesia upon repeat testing was
confirmed over a 2 week period by a single IFA,flow cytometry and PCR approximately
every second day and daily smear examination (data not shown). Flow cytometry and
blood smear examinations (modified Wright’s stain) were performed at MSU, and
serology (IFA) and PCR were performed at the North Carolina State University (NCSU)
Vector Borne Disease Diagnostic Laboratory. The 4 greyhounds were then given
intravenous liposomal clodronate at a single low dose of 0.5 ml/kg. Babesia status was
monitored over a 2 week period post-treatment by daily smear examination, and by flow
cytometry and PCR approximately every second day. The same study design was then
repeated at a medium liposomal clodronate dose of 1 ml/kg and then, finally, at a high
liposomal clodronate dose of 2 ml/kg except that, after the final dose of liposomal
clodronate, Babesia status was monitored for an extended post-treatment period of 4
weeks by daily smear examination, by flow cytometry and PCR every second day, and by
repeat serology. There were minor numerical non-significant increases in the numbers of
HE+ RBCs at various time points in greyhounds exposed to all three doses of LC (Figure
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4.3). Interestingly, a marked increase in the numbers of HE+ RBCs was found in an
unrelated canine patient with increased numbers of reticulocytes by CBC (Figure 4.4)
suggesting that the LC-related increases in greyhounds could be due to increased
numbers of reticulocytes, although daily CBCs performed on the 4 greyhounds did not
support this speculation. Based on lack of evidence of Babesia infection by blood smear
examination, PCR or serology at any point during the study period (data not shown), we
conclude that LC does not appear to be a reliable means of exposing occult babesiosis in
greyhounds with a recent history of harboring the organism. To investigate if the
numerical non-significant increases in HE+ RBCs numbers were due to the effect of LC,
RBCs from 3 healthy Walker hounds (see Methods, Chapter 5) exposed to the medium
dose of LC were assessed by flow cytometric analysis. There were no significant
differences in the numbers of HE+ RBCs in the LC-treated animals compared to the nontreated controls (data not shown) suggesting that the observed numerical increases in the
numbers of HE+ RBCs were not LC-related.
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Figure 4.3

Effect of LC exposure on numbers of RBCs exhibiting inclusion of HE in
greyhounds in Babesia canis-exposed greyhounds.

RBCs from 4 healthy but Babesia-exposed greyhounds treated with low (0.5 ml/kg),
medium (1 ml/kg), and high (2ml/kg) doses of LC were assessed by single color flow
cytometry approach. Data are expressed as a mean % of total RBCs. No statistical
significance indicated.

Figure 4.4

Flow cytometric analysis of RBC HE incorporation in the canine clinical
patient diagnosed with reticulocytosis.
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CHAPTER V
SELECTIVE LC-DEPENDENT REMOVAL OF PROFESSIONAL ANTIGEN
PRESENTING CELLS, MONOCYTES/MACROPHAGES, AND
IMMATURE DENDRITIC CELLS PROMOTES INCREASES
IN CD4+CD25+FOXP3+ REGULATORY T CELLS

Abstract
A critical component of host immune systems, regulatory T cells (Tregs) have
been described in detail in humans and mice. Although some researchers have begun to
study canine Tregs, comprehensive functional information has not yet been produced. We
evaluated the effect of depletion of professional antigen presenting cells (APCs) on the
levels and phenotypes of regulatory T cells (Tregs) in dogs treated with liposomal
clodronate (LC) by multi-color flow cytometric analysis. We demonstrate that numbers
of Tregs increased after administration of various LC doses in greyhounds, and the same
effect was found in Walker hounds by using the medium LC dose. Our study shows a
correlation between levels of CD14+ monocytes and Tregs in dogs treated with LC. These
data demonstrate that, as in humans, the population of CD4+CD25high T cells most
reliably identified as the highly enriched FOXP3+ Tregs in dogs. In addition, we defined
the CD4+CD25lowFOXP3+ cells as the major regulatory T cell subset affected by LC
exposure suggesting the role of monocytes in naïve T cell priming and differentiation into
Tregs.
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Introduction
An important aspect of the host immune system, regulatory T cells (Tregs) are a
known CD4+CD25+FOXP3+ subset of T cells which are responsible for maintaining
tolerance by suppression of natural immune responses [1]. These cells have been proven
to develop normally, and they can also be induced to develop as antigen specific Tregs
from conventional peripheral CD4+ T cells [2].
Although there is very little known about the functional significance of regulatory
T cells in the canine, Tregs are an important constituent of healthy function in the host
immune system. In normal systems when activated or increased in numbers to a suitable
concentration, Tregs can help to prevent autoimmune dysfunction of the host [3], or they
may only exacerbate a current problem [4]. Although more research is needed, studies
have shown that FOXP3 (forkhead box P3 transcription factor) is necessary for the
generation of naïve T cells into regulatory T cells with suppressive functions. Without
FOXP3, the recognizable immunosuppressive function can be lost [5].
Monocytes and macrophages are professional antigen presenting cells (APCs) that
express multiple phagocytic and signaling pattern recognition receptors (PRRs) that sense
and bind pathogen-associated molecular patterns (PAMPs) and produce cytokines [6,7,8].
Recent studies show that monocytes and macrophages are not limited to presenting
antigens to effector T cells and stimulating and shaping T cell-mediated immune
responses; they also prime naïve T cells, thus initiating adaptive immune responses
[6,7,8,9,10].
Liposomes have been proven to increase the effectiveness of certain drugs by
being used as drug carriers and allowing the liposome to follow its natural course,
42

undergoing phagocytosis. Clodronate (dichloromethylene bisphosphate), a small
hydrophilic molecule which functions to induce apoptosis via lysis of the mitochondrial
membrane of host monocytes, dendritic cells, and macrophages, is one such drug [11].
The overall effect on the immune system of administering liposomal clodronate is a
transient immune suppression which may be either detrimental or helpful to the host. It
can be seen in the depletion of the number of viable circulating monocytes and
macrophages [12]. Liposome encapsulated clodronate (liposomal clodronate, LC) is
currently being used in research in a variety of approaches that include: to selectively
deplete monocytes and macrophages to provide controls for evaluating muscle injury
[13]; to prove the role of the immune cells in dengue fever [14]; to accelerate alveolar
macrophage reconstitution [15]; to decrease dissemination and brain invasion of
Cryptococcus neoformans;[16], and to treat diseases such as gout and various
autoimmune diseases [17].
Current researchers in canine immunology utilize the specialized depletion tactics
made possible by LC, but have also begun to explore the unknown concerning regulatory
T cells.
In the current study, we assessed the levels and phenotypes of
CD4+CD25+FOXP3+ regulatory T cells in greyhounds and Walker hounds treated with
different doses of LC.
Materials and Methods
Dogs
Healthy adult greyhounds and Walker hounds were used for this study. Health
was confirmed based on physical examination, complete blood count (CBC), serum
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biochemistry, and urinalysis. CBC and serum biochemistry were completed by the
Mississippi State University College of Veterinary Medicine Diagnostic Laboratory
Services (CVM-DLS).All animals were cared for according to guidelines approved by the
Mississippi State University Institutional Animal Care and Use Committee (IACUC), and
were housed in a university setting under standard conditions. The Mississippi State
University animal facilities and program are accredited by the American Association for
Accreditation of Laboratory Animal Care.
Treatment
Liposome clodronate (LC) (dichloromethylenedisphosphonic acid disodium salt,
SIGMA, encapsulated into liposomes at Colorado State University) was administered to
four greyhounds at low (0.5 ml/kg), medium (1 ml/kg), and high (2 ml/kg) doses via slow
intravenous infusion at a constant rate into an indwelling peripheral venous catheter over
a 90-minute period, using an infusion pump.
In the Walker hound study, LC (Encapsula NanoSciences in Nashville, TN) was
administered to three Walker hounds as previously described at a single dose of 1 ml/kg.
In both studies, control dogs received no treatment.
Study Design
The design of the greyhound study is shown in Figure 5.1. Briefly, the study was
divided into baseline monitoring of Tregs in greyhounds prior to their treatment with
different doses of LC and the assessment of levels of regulatory T cells in LC-treated
dogs (Figure 5.1). Similarly to the greyhound study, the Walker hound study consisted of
the baseline and after the treatment monitoring of Tregs. However, the experimental
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animals were exposed only to the medium dose of LC, and their peripheral blood
monocytes levels as well as total cell blood counts were determined in addition to Tregs.

Figure 5.1

LC treatment timeline.

Arrows L, M, H indicate the low, medium, and high dose treatments. The dashes indicate
Treg assessment time points. (D-0/25/13) represents the number of assessment time
points in the study. (A) represents the greyhound study. (B) represents the Walker hound
study.
Reagents and Antibodies
BD Pharm Lyse™ (10X) lysing solution (BD Biosciences) was used to remove
red blood cells from the white blood samples collected in EDTA tubes.
Fluorescein -conjugated mouse anti-canine CD14 mAbs (LS-C43762, Lifespan
Biosciences, Inc.) were used to stain monocytes. Fluorescein -conjugated rat anti-canine
CD4 (LS-C127352, Lifespan Biosciences, Inc), Phycoerythrin (PE)-conjugated mouse
anti-canine CD25 (P4A10) and the FOXP3 Staining Buffer Set (including
Fixation/Permeabilization Diluent, Fixation/Permeabilization Concentrate, 10X
Permeabilization Buffer) and allophycocyanin (APC)-conjugated rat anti-canine FOXP3
mAbs (FJK-16s) (all from eBioscience Inc.) were used to stain regulatory T cells.
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Cell Preparation
Monocytes
Whole blood samples collected in EDTA were incubated with Fluoresceinconjugated anti-CD14 mAbs for 30 minutes in the dark at 4°C. To lyse and remove red
blood cells, samples were incubated with BD Pharm Lyse ™ lysing buffer for 15 minutes
in the dark at room temperature, gently vortexing every 5 minutes. The resulting cell
populations were washed and analyzed by flow cytometry.
Regulatory T cells
Whole blood samples collected in EDTA were incubated with Fluoresceinconjugated anti-CD4 and PE-conjugated anti-CD25 mAbs for 30 minutes in the dark at
4°C. To remove red blood cells, samples were incubated with BD Pharm Lyse ™ lysing
buffer for 15 minutes in the dark at room temperature, gently vortexing every 5 minutes.
Red blood cells were removed, and the remaining cell populations were washed and
stained with anti-FOXP3 staining buffer set following the manufacturer’s instructions.
Briefly, cells were incubated with fixation/permeabilization solution for 30 minutes in the
dark at 4°C, washed twice with permeabilization buffer followed by incubation with
APC-conjugated anti-FOXP3 mAbs for 30 minutes in the dark at 4°C. After a single
wash, cells were then analyzed by flow cytometry.
Flow Cytometry
Red blood cell depleted canine cells were gated based on their relative size and
granularity using forward and side scatters (FSC and SSC, respectively) with
FACSCalibur Flow Cytometer (Becton Dickinson). Immunofluorescent stainings were
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analyzed using FlowJo 7.6.4 Software (Tree Star, Inc.). The CD14 immunofluorescent
staining in canine monocytes was analyzed by using single histogram statistics (Figure
5.2). A three-color analysis was performed to assess the FOXP3 staining by gating on
CD4+CD25+ double positive T cells and analyzed by using single histogram statistics
(Figure 5.3). In addition, the intensity of the CD25 fluorescence in the CD4+FOXP3+
cells was assessed by using dot plots with multiple gate statistics (Figure 5.4).

Figure 5.2

Assessment of CD14+ monocytes by flow cytometry.

RBC- depleted canine cells were gated based on their relative size and granularity using
forward and side scatters (A). The CD14 immunofluorescent staining in canine
monocytes was analyzed by using single histogram statistics (B).
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Figure 5.3

Identification of CD4+CD25+FOXP3+ regulatory T cells by three color
flow cytometry approach.

RBC- depleted canine cells were gated based on their relative size and granularity using
forward and side scatters (A). Two color analysis for the CD4+CD25+ T cells was
performed by using dot plots with quadrant statisics (B). The FOXP3 staining intensity
was analyzed by using single histogram statistics (C).
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Figure 5.4

FOXP3 expression in peripheral blood of CD25low, CD25medium, and
CD25high CD4+ T cells.

The CD4+ T cells were gated based on the brightness of CD25 staining (A). FOXP3
histograms of T cells of low, medium, and high CD25 fluorescence intensity (B,C,D,
respectively).
Statistical Analysis
Regulatory T cell marker-specific populations were expressed as a percentage of
the total lymphocyte numbers or as absolute cell numbers. CD14+ monocyte populations
were expressed as a percentage of PBMC. Then, data was subjected to a one-way
analysis of variance (ANOVA) followed by Fisher’s LSD multiple comparison post hoc
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test and are presented as means + SD. The level of significance for all tests of effects was
set at P<0.05.
Results
Liposomal clodronate exposure promotes increases in the levels of
CD4+CD25+FOXP3+ regulatory T cells in greyhounds
To characterize effects of the monocyte depletion on the levels of Tregs in dogs,
we treated 4 healthy greyhounds with different doses of LC and assessed the levels of
peripheral blood Tregs by flow cytometry. Percentage of CD4+CD25+FOXP3+ Tregs
significantly increased in greyhounds treated with low and medium doses of LC (Figure
5.5). Although the percentage of Tregs in dogs treated with high dose of LC increased,
these increases were non-significant (Figure 5.5).

Figure 5.5

LC exposure promotes increases in regulatory T cell populations in dogs.

Regulatory T cells from 4 healthy greyhounds exposed to low (0.5 ml/kg), medium (1
ml/kg), and high (2 ml/kg) doses of LC were assessed by three color flow cytometry
approach. Data are expressed as a mean % Tregs of total PBMC. (a b) indicates treatment
differences (P<0.05).

50

Effects of LC treatment on the peripheral blood regulatory T cell and monocyte
fluctuations in Walker hounds
To further investigate possible mechanisms of LC-dependent regulatory T cell
fluctuations, we assessed the levels of CD4+CD25+FOXP3+ Tregs and CD14+ monocytes
in Walker hounds challenged with medium dose LC. As expected, LC treatment
promoted decreases in CD14+ monocyte numbers in all experimental dogs after 24hrs of
treatment, followed by significant increases during compensatory period (4-7 days post
treatment) and declining to initial baseline levels after 8-11 days of LC challenge (Figure
5.6, C). In general, the LC-dependent Tregs fluctuations were similar to the changes in
the levels of CD14+ monocytes. However in contrast to the monocyte levels, the
percentage of Tregs after 24hrs of treatment showed only slight non-significant decrease
(Figure 5.6, A). Next, we evaluated the absolute numbers of Tregs in the peripheral blood
of Walker hounds before and after LC treatment. Figure 5.6, B demonstrates a significant
decrease in the Treg numbers after 24hrs of LC treatment, an expected compensatory
increase and a significant recovery of Tregs during the normalization period.
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Figure 5.6

Effects of LC treatment on the levels of CD4+CD25+FOXP3+ regulatory T
cells and CD14+ monocytes in peripheral blood of Walker hounds.

Regulatory T cells and monocytes from 3 healthy dogs exposed to medium dose of LC (1
ml/kg) were assessed by three and one color flow cytometry analysis, respectively. (A) %
Tregs of total lymphocytes; (B) absolute numbers of Tregs; (C) % monocytes of total
PBMC; (1) Baseline levels[prior to treatment]; (2) Initial response to LC [24 hours post
treatment]; (3) Compensatory response to LC [4-7 days post treatment]; (4)
Normalization [8-11 days post treatment]. Data are expressed as a mean % of total
PBMC (A,C) or as mean absolute cell counts (B). (a b *) indicates group differences
(P<0.005).
CD4+CD25lowFOXP3+ are the major regulatory T cell subset affected by LC
exposure
Previously reported data in humans demonstrated that although CD4+CD25+ T
cells contain Tregs, other cells such as recently activated pathogenic T cells may also fall
in this phenotypic subset [29]. The top 2% CD4+CD25bright T cells most reliably
identified a highly enriched FOXP3+ Tregs. To identify the population of Tregs
selectively targeted by LC we applied multiple gate statistics for the assessment of CD25
fluorescence intensity in CD4+CD25+FOXP3+ T cells (Figure 5.7). There was a
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numerical decline in % of Tregs expressing low, medium and high levels of CD25 two
days after treatment, followed by an increase, which was significant only in
CD4+CD25low FOXP3+ Tregs. The levels of Tregs in all three populations with
differential expression of CD25 after two weeks of LC exposure were comparable with
their levels prior to the LC treatment.

Figure 5.7

LC exposure promotes significant increases in the most recently activated
CD4+CD25lowFOXP3+ Tregs.

CD4+FOXP3+ T cells from the dogs exposed to LC were gated based on brightness of
CD25 staining resulting in separation into low, medium, and high expressers of CD25.
(1) Baseline levels [prior to treatment]; (2) Initial response to LC [24 hours post
treatment]; (3) Compensatory response to LC [4-7 days post treatment]; (4)
Normalization [8-11 days post treatment]. Data are expressed as mean % of total Tregs.
(a b) indicates group differences.
Discussion
Adequately described in humans and mice, regulatory T cells
(CD4+CD25+FOXP3+ T cells) are an essential requirement for the healthy function of the
mammalian immune system as they function to modify or inhibit effector cells. This
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makes them a double edged sword. When functioning properly, they help to maintain
homeostasis within the immune response, but if malfunctioning or absent, they can
impede beneficial immune responses, and systemic and/or organ-specific autoimmunity
can result [19].
Little is known about the functional purpose and clinical relevance of Tregs in
canines, but results from recent studies have provided initial phenotypic and functional
characterizations of Tregs within the canine system [20, 21, 22]. Current research
objectives include understanding Tregs across a wide range of disease models. The
results of current studies indicate that increased numbers of Tregs are associated with
disease consequence [22, 23, 24, 25, 26, 27]. This study expands previous research to
include new breeds of healthy dogs, while observing variation between numbers of Tregs
in greyhounds and Walker hounds.
In the current study, the overall effect of the differing doses of LC on the
experimental dogs was assessed during the greyhound study. As previously mentioned,
LC has many uses in the treatment of autoimmune diseases as well as research [13, 14,
15, 16, 17, 18]. The goal in using LC was to transiently knock out the immune system by
initiating a period of monocyte/macrophage/DC depletion, thus allowing us to evaluate
the levels of decrease or generation of regulatory T cells over the defined treatment
period.
For each dog, a similar pattern was observed in the levels of Tregs in response to
each dose (low, medium, high). The overall health of the dogs also varied. At the low and
medium dose, no clinical signs or negative effects were witnessed in the dogs. While at
the high dose, dogs developed clinical signs including transient fever, diarrhea, clear
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nasal discharge, and general malaise. To this end, the medium dose (1 mg/kg) was chosen
to be utilized in the Walker hound study. This dose allowed resultant changes in Treg
levels to be observed while avoiding the development of clinical signs.
For the first time, this study evaluated numbers of canine regulatory T cells in the
absence of professional antigen presenting cells (APCs), monocytes, and immature DCs
by utilizing LC. In the greyhound study, the number of Tregs after a visible profound
decline (during the initial response phase, 24 hrs post treatment) significantly increased
when dogs were treated with the low and medium dose, and while the high dose also
resulted in increase in Tregs, no significance was observed.
The relationships between monocytes/macrophages and Tregs within the canine
model are unknown. Recent studies have expanded the role of monocytes and
macrophages beyond presenting antigens to effector T cells and stimulating T cell
mediated immune responses. They also are responsible for initiating adaptive immunity
via priming of naïve T cells, triggering the generation of new Tregs, a critical subset of T
cells [6,7,8]. Therefore, in the Walker hound study, both monocyte and Treg numbers
were assessed simultaneously. The significant decreases in monocyte numbers in all
experimental dogs 24 hrs after treatment was expected and reflects the expected
mechanism of action of LC. When the bisphosphonate clodronate is incorporated within
liposomes, phagocytosis by monocytes/macrophages and immature DCs is enhanced
[28]. Lysis of the mitochondrial membrane of host cells by LC induces apoptosis
resulting in the transient depletion of monocytes [11]. At the same time, absolute Treg
numbers were also evaluated showing significant compensatory gains as well as the
significant recovery of Treg numbers during the normalization period. In theory, these
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compensatory gains reflect initiation of adaptive immune response by production of new
Tregs via activation from naïve T cells in the periphery.
As a part of the Walker hound study, we produced data that mirrors information
reported in human Tregs that, although canine CD4+CD25+ T cells contain Tregs, other
cells such as recently activated pathogenic T cells may also fall in this phenotypic subset.
The top 2% CD4+CD25bright T cells most reliably identified a highly enriched FOXP3+
Tregs in dogs. We report that CD4+CD25lowFOXP3+ is the major regulatory T cell subset
affected by LC exposure, showing the significantly increased numbers after 4-7 days of
LC-treatment. These increases suggest the active recruitment and generation of Tregs
from naïve CD4+ peripheral blood T cells.
In conclusion, further research is essential in creating a working understanding of
canine CD4+CD25+FOXP3+ Tregs, and the role of professional APCs monocytes and
DCs in their generation. Tregs are a critical subset of immune cells which are produced
during T cell development in the thymus and can be induced in the periphery from naïve
T cells to provide antigen specific inhibition in cases of infection or disease.
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